- Home
- NEWP vs LTGO Comparison
NEWP vs LTGO Comparison
Compare NEWP & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NEWP | LTGO |
|---|---|---|
| Founded | 1972 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2006 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NEWP | LTGO |
|---|---|---|
| Price | $5.97 | $23.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 599.2K | 206.3K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $17.22 |
| 52 Week High | $7.55 | $25.93 |
Technical Indicators
Market Signals| Indicator | NEWP | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 67.70 |
| Support Level | $3.44 | $21.26 |
| Resistance Level | $6.31 | $25.47 |
| Average True Range (ATR) | 0.41 | 2.02 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 3.38 | 61.89 |
Price Performance
Historical ComparisonAbout NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.